The substantial modifications included in the amendment 1 of the protocol are: - to specify the conditions for resuming treatment for patients who have stopped treatment at the M24 visit according to the immunovirological criteria - to modify the quantity of blood planned for the biobank - to add patients who do not stop treatment at M24 to the analysis planned at M30 for the complementary immunological study "Analyse de la capacité de suppression virale des lymphocytes T CD8+ ex vivo" - to update the list of participating sites (closure of two investigating sites and change of address for another investigating site) - to add a new member to the scientific board - to identify a realeasing site for one of the trial products (darunavir)

The substantial modifications included in the amendment 2 of the protocol are: - to submit the protocol for carrying out the mucosal reservoir sub-study (rectal biopsy) with some modifications concerning the routing and the number of biopsies to be taken. This sub-study had been presented in the protocol, notably in the follow-up schedule, bu the specific modalities of analysis were not yet specified. - to use the biological assessment dated less than 7 days before the D-8 visit as a pre-inclusion assessment (in order to be able to include patients in a shorter time frame) - to add HBV serology to the D-8 pre-inclusion assessment - to remove the inclusion criterion "inclusion within 10 weeks following the date of diagnosis of primary HIV infection" present in the protocol - to replace a member of the scientific board - to close two investigating centres and add a new one - to change the principal investigator of a centre - to change the formulation of one of the drug (Norvir) from capsules to tablets.

The substantial modifications included in the amendment 3 of the protocol are: - to offer the complementary study "Analysis of deep reservoirs from rectal biopsies" at the M24 visit to all included patients from dedicated centres - to submit the self-questionnaires (D-8, M18 and M30) for the evaluation of the "OPTICE" device - to change the principal investigator at two sites.

The substantial modifications included in the amendment 4 of the protocol are: - to change of trial sponsor - to update the list of members of the Scientific Council - a patient information note on the progress of the trial, the change of promotion and the complementary information and support system.